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ABSTRACT 
 
Characterization of neuropeptides is still actively underway.  Various resources, both 
animal and instrument, were utilized to best answer the questions about the presence of peptides. 
Aplysia californica cerebral neurons were used to verify predicted peptide processing of the 
putative prohormone AC2. However, the peptides were found to be absent in the forms given by 
the predictive software when analyzed with MALDI MS. Later studies used Rattus norvegicus 
brain tissue or microdialysate to look at dynamic peptide responses. The first compared pre- and 
post-stimulation profiles of rat brain slices that were exposed to a general stimulant. Though a 
stimulation affect was not seen, many peptides known to be present of the regions of interest, the 
suprachiasmatic nucleus and supraoptic nucleus, were observed. The final study involved creation 
of a peptide database for the hippocampus through high resolution mass spectrometry with which 
to reference microdialysate peptides. The rats were also exposed to various treatments including 
acute morphine, though the rats were most strongly distinguished by animal and not treatment via 
principal component analysis. A few peptides from the created hippocampus database were 
identified to also be in the microdialysate, while there was an interesting pair of fibrinogen 
protein fragments in the microdialysate that was not seen in the hippocampal extracts. The 
cumulative approach used in this work allows neuropeptide signaling to be characterized during 
behavior, enabling new insights into the functions of neuropeptides.  
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CHAPTER 1 
 
INTRODUCTION AND SUMMARY OF RESEARCH 
 
Characterization of neuropeptides and hormones is still actively underway. The many 
aspects of their existence—chemical, spatial and temporal—can be examined separately or 
together with an equally diverse set of tools. The goals of the Sweedler research group are to 
develop instrumentation and sampling techniques to accommodate optimal conditions to answer 
the implied biological questions of identity, distribution and function of neurotransmitting 
molecules. This is accomplished mainly through various collection and separation methods 
coupled to mass spectrometry to provide accurate masses used for determining neuropeptide 
identities. Along with the correct tools, a fitting specimen is necessary to investigate the desired 
scope of interest. The work described here used two animal model systems of the many utilized 
by the group to best represent a measurable behavior, function,  or neural system.  
Chapter 2 describes the use of the invertebrate animal model, Aplysia californica that was 
chosen for the extensive background known about the neural system and the ease in studying their 
relatively large neurons and cluster anatomy. The well-mapped cells and connections naturally 
lead to the next step of attempting to understand their communication, which is where 
neuropeptide expression and processing information becomes an important building block. The 
search for a specific prohormone’s peptide products in a discrete neural cluster tries to answer the 
question of cell contents. The expression of the products in the predicted cluster would connect a 
signaling molecule to a group of cells, which are in turn linked to cell connections and ultimately, 
to pathways and function.  
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The work described in Chapter 3 goes one step further in addressing tissue contents and 
their natural dynamics in living, responding tissue. Brain slices from the rat, Rattus norvegicus, 
were obtained, equilibrated in a bio-mimicking environment and allowed to respond to stimuli. 
Measurements were taken before and after the stimulus to be able to correlate the peptide changes 
to the stimulant. The stimulus of choice, KCl, provided a massive release event of the peptide 
reserve pool but other conditions could be used with this technique to probe increasingly specific 
release reactions. The implied future intention is to find the specific regulators of the two nuclei 
studied since they are known to be peptidergic regulators of body processes, or the “regulators of 
the regulators”. 
Chapter 4 is yet another step further; it incorporates peptide presence in a specific tissue, 
dynamic release, and the new aspect of a correlated observable behavior in a live subject. 
Sampling of the extracellular fluid was done via in vivo microdialysis while the rat was exposed 
to various conditions. Morphine was given as a stimulant condition followed by a measureable 
working memory task to assess an effect from the drug. The stimulation of the maze could also be 
treated as another stimulant condition itself. Discovering the peptide-condition relationship was 
also aided by supplementary sequencing information from the same hippocampal tissue. This 
brought identity information from the peptide level, reversed from the identity resource of the first 
Aplysia study. Though there is a common thread of peptide characterization throughout the 
studies, different tool, both animal and instrument, are needed to most efficiently answer the 
questions of interest.  
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CHAPTER 2 
 
INVESTIGATION OF THE EXPRESSION AND PROCESSING 
OF APLYSIA CALIFORNICA PROHORMONE AC2 
 
 
 
NOTES AND ACKNOWLEDGEMENTS 
This work involves a collaboration between the Sweedler group and Sven Vilim and 
Klaudiusz Weiss from Mt. Sinai Medical School who supplied the gene sequence and in situ 
images. Dr. Elena Romanova is gratefully acknowledged for guidance and discussion regarding 
this material along with Dr. Fang Xie and Dr. Adriana Bora for further discussion and 
suggestions. Xiying Wang is also acknowledged for her dissection contributions and expertise. 
This material is based upon work that was supported by the National Institutes of Neurological 
Disease and Stroke through R01NS031609. 
 
 
2.1 BACKGROUND 
 The cerebral ganglion of the Aplysia californica serves as processing center for various 
routes of receiving sensory information from other ganglia and the environment as well as 
sending motor commands. It consists of 15 discrete neuron clusters (7 bilateral pairs and 1 
unpaired) with tens of visibly identifiable cells in each (JahanParwar 1976, Fredman 1975). The 
vast numbers of neurons forming connections in the cerebral ganglion enable the animal 
behaviors required for survival.  These connections are either electrical or chemical, with the 
latter involving small molecule neurotransmitters and the peptide-based neuromodulators. 
Characterizing these signaling molecules aid our understanding of neuronal network function.  
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 More than a decade ago, the Sweedler group was approached about finding peptide 
modulators within the cerebral ganglion neurons, and we turned to our other long term 
collaborators for help in determining these. Vilim and Weiss used a unique representation 
difference analysis approach to find peptide prohormone genes in this cluster (Jing 2010). One of 
these named AC2 (A-cluster clone 2), had in interesting structure suggesting it was a 
neuropeptide, and both western and in situ data were used to determine its localization. They 
confirmed it was expressed in A-cluster at high levels, with less but significant staining in the 
cerebral F-clusters. However, the enzymatic processing from RNA to peptide is complex because 
of the number of enzymes involved makes predicting final peptides problematic (Li 2008). Its 
processing and presence at the peptide level was investigated here through the use of direct 
MALDI MS of neurons and neuronal tissue chemical extractions.  
 
2.2 EXPERIMENTAL  
2.2.1 Animals. Adult Aplysia californica were obtained from Charles Hollahan (Santa Barbara 
Marine Bio., Santa Barbara, CA). Animal subjects were maintained in continuously circulating, 
aerated, and filtered seawater (Instant Ocean; Aquarium Systems, Mentor, OH) chilled to 14 °C.  
 
2.2.2 Sample Preparation. Adult Aplysia californica weighing between 200 and 300 g were 
anesthetized by a ventral injection into the vascular cavity of 390 mM MgCl2 in water equal to 
one-half to one-third the animal’s body weight. Ganglia and connected nerve tissue were 
dissected out and placed in artificial seawater (ASW all in mM:  460 NaCl, 10 KCl, 10 CaCl2, 22 
MgCl2, 26 MgSO4, 2.5 NaHCO3 and 10 HEPES, pH 7.7) supplemented with antibiotics (100 
units/mL penicillin G, 100 µg/mL streptomycin, and 100 µg/mL gentamicin). The ganglia were 
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then incubated in 1% protease (Type IX, Roche Diagnostics) in ASW-antibiotic solution at 34°C 
for 30-60 min, depending on animal size, to enzymatically digest some of the surrounding sheath 
tissue for improved isolation specificity. After treatment, the ganglia were washed in ASW and 
then transferred to ASW-antibiotic solution. Under visual control with microscope assistance 
(Leica MZ 7.5 high performance stereomicroscope, Leica Microsystems, Bannockbum, IL), A-
cluster cells are manually isolated from the cerebral ganglion with sharpened tungsten needles and 
scissors. A similar protocol is also described in Lapainis 2009. 
 
2.2.3 Extraction. This protocol is also described in Bora 2008. Manually isolated cells were 
either used for direct cell analysis or extracted. When used for direct analysis, the cells/clusters 
were placed directly on a steel MALDI target with the sharpened tungsten needles.  The cells 
were then ruptured and smeared onto the sample spot and then serially spread onto subsequent 
spots for a dilution affect followed by dried-droplet matrix application of 2,5-dihydroxybenzoic 
acid (DHB; 50 mg/mL in 50:50 acetone: deionized water).  For extraction of the peptides, 10-15 
cells were transferred into a microcentrifuge tube with 50 µL of acidified acetone (40:6:1, 
acetone/water/conc. HCl) with removal of ASW before addition of extraction solvent. Manual 
homogenization was then performed for approximately 1 min with a pellet pestle (Kimble Chase, 
Vineland, NJ) to enhance extraction. The samples were then centrifuged at 14,000 × g and 15 °C 
for 10 min. The supernatant was retained and concentrated to 7-10 µL.  
 
2.2.4. Signal P 3.0 and NeuroPred. Online software was used to predict the peptide sequences of 
the AC2 prohormone. Signal P 3.0 predicted the length of the prohormone signal sequence that 
would be cleaved off before further peptide processing (Bendtsen 2004). Selected parameters 
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included eukaryote organism group and both the neural network and hidden Markov model 
methods. NeuroPred (UIUC) was then used to predict cleavage sites after indication of the signal 
sequence length (Southey 2006, Hummon 2003). Output sequences were manually confirmed by 
predicting cleavages after dibasic sites.  
 
2.2.5 Matrix Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry 
(MALDI-TOF MS). MALDI-TOF MS data was acquired on an Ultraflex II TOF/TOF MS 
instrument (Bruker Daltonics, Bremen, Germany). Samples were spotted (either smeared cells or 
0.5 µL extract spots) onto a steel MALDI target and covered with approximately 0.7 µL of DHB 
matrix. Samples were allowed to dry before insertion into the instrument. Mass spectra were 
obtained in reflectron mode within 100 ppm mass accuracy. The mass-to-charge (m/z) range was 
450-5000 with variable accumulations of shots (200-1000). Bruker FlexAnalysis software was 
used for spectra visualization and picking of peaks signal-to-noise 3 or greater. 
 
2.3 RESULTS AND DISCUSSION 
The gene product AC2 is a putative prohormone based on sequence markers until other 
hallmarks of neuropeptides are confirmed. To help discover these products, in situ hybridization 
via a whole mount tissue image stained for AC2 mRNA transcripts (provided by Vilim with 
protocol described in Vilim 2001) is used as a map to guide cell selection (Figure 2.1). Then using 
the mass spectrometry tool MALDI-TOF MS, the final peptide products are measured  by 
measuring the mass-to-charge values of the peptides present in the neurons. However, even with 
location information, the actual bioactive peptides are difficult to predict due to posttranslational 
processing like cleavage and chemical modifications (Xie 2010). 
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    Preliminary predictions can be made using available online software that can calculate the 
most likely prohormone processing site cleavages using databases of known prohormone 
processing and cleavage predictions based on algorithms and a logistic regression model 
(Bendtsen 2004, Hummon 2003). The predicted products of the AC2 prohormone were four 
amino acid sequences separated by dibasic sites with one likely to also be amidated as shown in 
Table 2.1. This then provides a probable list of masses to look for within the direct tissue and 
tissue extracts.  
Measurement of both types of cell extracts from the indicated A-cluster cells reveal 
profiles of detected peptides (Figure 2.2). The spectra show some conserved peaks throughout the 
samples as well as differences indicating variations from cell-to-cell. The first two spectra of 
Figure 2.2 show the advantage of serial smears; successive smears have less salt and signal is not 
competing with salt adducts. The spectra were searched specifically in the mass ranges of the 
predicted peptides. In three separate experiments, the four predicted peptides were not detected 
(e.g. the absence of the GSWN peptide in spectrum C of Figure 2.2). Their absence suggests that 
AC2 peptide products may not be expressed or detected in the predicted forms. This can be true 
for a number of biological and analytical reasons. Biologically, if the predicted sequences are 
correct, the peptides may not be present in those cells because they are dependent on the specific 
state of the animal (e.g. age, satiation/hunger, etc.) as in Floyd 1999 when insulin peptides were 
shown to decrease with food deprivation. It could be that the peptides are present but below the 
detection limit. The issue could also be in the mRNA staining. It could be detecting a similar but 
unrelated mRNA than the AC2 target (Manning 1998).  
 
 
 
 8 
 
2.4 FUTURE DIRECTIONS 
 To further investigate the validity of AC2 as a peptide precursor that may be expressed in 
the cerebral ganglia A-clusters, other routes should be utilized. The pooled extracts of the clusters 
could be run on an instrument that offers fragmentation and sequencing capabilities (MS/MS). If 
any portion of the AC2 sequence was detected there, this would give strong evidence of 
expression of AC2 in some form. More predictive work may be done to consider alternative 
cleavages as may be also indicated by the MS/MS results. Consideration of post-translational 
modifications and even secondary structure (i.e. the possibility Cys-Cys bonds due to the high 
number of Cys residues) would provide more probable masses to verify in sample spectra.  
 In regards to in situ hybridization, the F-clusters could also be examined for the same 
peptides. If they reveal similar results then the source sequence of the hybridization could be 
reexamined for an alternative that could reconfirm the presence or absence of AC2 expression in 
the Aplysia cerebral ganglia. 
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Table 2.1 List of peptide sequences and corresponding calculated M+H from AC2 predicted with 
Signal P 3.0 and NeuroPred online software (Bendtsen 2004, Southey 2006, Hummon 2003). 
 
 
Sequence [M+H] calc. 
GSWN 463.19 
GPLDPCVFQCMRGVLKC 1865.89 
TQAANTCNNNGHQHVPDFDDVVDLGQRFY 3275.46 
EQSVVGLSQKVDCCQKYKMCYLVCRPDAESVPPCGGAK + amidation 4117.95 
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CHAPTER 3 
 
EX VIVO COLLECTION AND DETECTION OF THE RATTUS 
NORVEGICUS SUPRACHIASMATIC NUCLEUS AND 
SUPRAOPTIC NUCLEUS PEPTIDE RELEASATE 
 
 
NOTES AND ACKNOWLEDGEMENTS 
This work involves a collaboration between the Sweedler and Martha Gillette research 
groups.  Dr. Shifang Ren and Dr. Norman Atkins are acknowledged for their guidance in the SCN 
and SON release experiments. Dr. Stanislav Rubakhin and Agatha Luszpak are also 
acknowledged for their dissection contributions and expertise. This material is based upon work 
that was supported by the following agency and grants: National Institutes of Health NS031609 
and DA018310.  
 
3.1 BACKGROUND 
The suprachiasmatic nucleus (SCN) and supraoptic nucleus (SON) are peptidergic brain 
regions that function in regulatory processes through the use of a variety of cell to cell signals 
(Lee 2010, Bora 2008). Release of neuropeptides and hormones is one form of their chemical 
signaling. The peptides are released from dense core vesicles into the extracellular space to 
diffuse to their targets (Bergquist 2009, Strand 1999). While it can be difficult to monitor peptide 
release in an intact organism, one can use brain slices maintained in vitro (the so called ex vivo 
brain slice preparation) to study mechanisms of release and the actual released species. This 
information gives a dynamic and functional picture of those particular tissues. Different tissues 
can release distinct sets of peptides with different stimulants, or one can use a generic stimulant, 
KCl, to study release from any neural tissue by depolarizing the membrane to produce a massive 
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release event of its vesicular pool. When working with a tissue slice maintained in a brain slice 
chamber, the released peptides do not reach their cellular targets but are released into the chamber 
where they could be collected.  One can relate the specific “cocktails” of release peptides to 
specific tissues and stimuli. A connection between the release of peptides to even a general 
stimuli provides functional implications.   Here my progress in using ex vivo brain slice 
preparation to monitor peptide release from the SCN and SON are highlighted.  The research 
involves efficiently collecting the peptide release using solid phase extraction protocols and then 
characterizing the released peptides with mass spectrometry. 
 
 
3.2 EXPERIMENTAL  
3.2.1 Animals. Adult male Sprague-Dawley rats (Harlan Laboratories, Madison, WI) were caged 
individually with food and water available ad libitum and maintained on a 12 hr light-dark cycle 
(lights on at 0800). All procedures concerning the animals were approved by the University of 
Illinois at Urbana-Champaign Institutional Animal Care and Use Committee and were in 
compliance with the National Institutes of Health Guide for the Care and Use of Laboratory 
Animals. 
 
3.2.2 Sample Preparation. After decapitation the brain was removed and rinsed with 
approximately 1 mL ice cold Earle’s balanced salt solution (EBSS, all in mM: 1.8 CaCl2 • 2H2O; 
0.81 MgSO4; 5.4 KCl; 26 NaHCO3; 116 NaCl; 1.0 NaH2PO4, 5.6 D-glucose). The tissue block 
(approximately 0.5 × 1.0 × 0.5, L × W × H in cm) was superglued (rostral side down with dorsal 
side facing blade) to the specimen tray of a Vibratome (Vibratome 3000 Series; Ted Pella, 
Redding, CA) and then submerged in ice cold EBSS bubbled with 95% O2/5% CO2. 400-µm 
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thick coronal slices were shaved off the tissue block until the SCN and SON were present in the 
same plane for several slices. These slices were transferred to an EBSS-filled chamber via large 
pasteur pipette.  
 
3.2.3 Brain Slice Chamber Instrumentation. The brain tissue slices were sustained in a brain 
slice chamber (BSC1; Scientific Systems Designs Inc., Mississauga, ON) with circulating EBSS 
heated in a lower chamber to 41 °C. An elevated reservoir of EBSS was used to refill the brain 
slice chamber by a pressure difference while chamber EBSS is removed by vacuum. The tissue 
was placed on a net insert allowing the tissue to be submerged less than 1 mm below the EBSS 
surface. Two metal stands with fine controls stood on either side of the brain slice chamber to 
hold the sampling devices. Each suspended the tip of a C18-packed pipette (ZipTip; Millipore 
Corporation, Billerica, MA) within 1 mm of the tissue surface (while still below the EBSS 
surface) and was connected to a syringe pump under negative pressure (0.2 µL/min). Set-up and 
technique are also described in Hatcher 2008.  
 
3.2.4 Sampling and Stimulation. The areas of interest (SCN and SON) were located visually and 
stimulated by the direct addition of 5 µL of 1 M KCl (5 µL per brain region). Prestimulation and 
stimulation collections were done over 20 min (each time with new a ZipTip). The stimulation 
collection was started immediately prior to the addition of the KCl.  
 
3.2.5 Solid Phase Extraction. After collection the ZipTips were either immediately washed and 
eluted onto a pre-spotted MALDI target or temporarily stored until the end of the experiment in 
20 µL of water in 0.6 mL microcentrifuge tubes (siliconized, low-retention; Fisher Scientific). 
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The protocol for ZipTip conditioning consisted of pipetting 20 uL of each of the following 
solution sequence:  50:50 ACN:water, water, EBSS. The washing consisted of rinsing the ZipTip 
with 20 uL of water. Finally the elution used 70:30 ACN:water. Elution was carried out directly 
from the ZipTip onto the analysis target through the use of a 100 µL Hamilton blunt syringe by 
introducing the elution solvent from the inner side of the ZipTip. Each sample was eluted as 5-6 
0.2 µL spots and was allowed to air dry before analysis. Eluted samples were stored on the target 
in a case and storage bag at 4 °C before analysis.   
 
3.2.6. Matrix Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry 
(MALDI-TOF MS). MALDI-TOF MS data was acquired on an Ultraflex II and Ultraflextreme 
TOF/TOF MS instruments (Bruker Daltonics, Bremen, Germany). Samples were eluted and 
spotted onto a Bruker/Eppendorf pre-spotted anchor chip target with alpha-cyan-4-
hydroxycinnamic acid (CHCA) matrix along with pre-spotted calibrants on dedicated positions. 
Mass spectra were obtained in reflectron mode within 100 ppm mass accuracy. The mass-to-
charge (m/z) range was 600-6000 with variable accumulations of shots (200-1000). Bruker 
FlexAnalysis software was used for spectra visualization and picking of peaks over signal-to-
noise 6.   
 
3.3 RESULTS AND DISCUSSION 
Ex vivo stimulation and collection of peptides from regions of interest on brain tissue 
slices require bio-mimicking conditions to allow for release and to sustain the tissue throughout 
the sampling process. A temperature regulated and oxygen-supplemented system that constantly 
replenishes the slice with a fresh balanced salt environment allows for viability of the tissue to be 
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maintained. The brain slice chamber shown in Figure 3.1 was used to hold and maintain the brain 
tissue slice during sampling. 
Collection of release has been carried out through various solid phase extraction (SPE) 
methods. Porous polymer monoliths (Ianncone 2009), SPE beads (Hatcher 2005) and 
functionalized surfaces in microfluidic devices (Jo 2007) have all been used to capture released 
peptides through the interaction of hydrophobic regions, which allows for separation from their 
native salt-rich environment that can hinder mass spectrometric detection. In this work C18-
packed pipettes were used for the capture of peptide analytes, similar to work in Rubakhin 2001. 
Figure 3.1 shows two such suspended ZipTips to be used in peptide extraction from direct tissue. 
Released peptides are drawn to this conditioned SPE material through negative pressure and are 
allowed to bind over a sampling time period. The bound sample can then be desalted and 
carefully eluted by a small volume of high organic (Figure 3.5.2) onto a MALDI target with 
prespotted or manual addition of matrix. This method allows for the MALDI MS detection of 
peptides from live brain slices as shown in Figure 3.3. As evidenced in the inset, the use of a TOF 
mass analyzer allows for high resolution mass spectra to be collected with the baseline resolution 
of isotope peaks possible. The peaks also exhibit high mass accuracy (<100 ppm), allowing for 
the identification of the detected peptides using MS spectra alone. This can be accomplished by 
mass-matching to previous studies which utilized fragmentation (MS/MS) to characterize the 
same intact masses from tissue extraction studies of the same model system such as in Lee 2010 
and Bora 2008. The use of this process allows for confident identifications even without the larger 
sample volumes required for quality MS/MS spectra, which cannot easily be attained with a 
sample limited brain slice experiment.   
 19 
 
A comparison of peptide profiles of the baseline and stimulated release states can be made 
to suggest which peptides are released in a stimulation-dependent manner, and hence more likely 
to be  bioactive, and perhaps even linked to a brain function. The desired result is to find a 
consistent change correlated with a specific stimulation, something that the Sweedler group had 
done with SCN release as a function of time of day (Hatcher 2008).  
Here, unfortunately, my attempts to determine consistently released peptide profiles by 
comparing pre- and post-stimulation of the SCN and SON did not exhibit new patterns. Often the 
only difference was a change in signal intensity, but this was without a consistent trend as seen in 
Figure 3.4. Intensity and resolution were improved with the use of a higher performance 
instrument; however, sources of inconsistencies from the sampling process overshadowed the 
enhanced analysis. An inherent difficulty is the repositioning of the second ZipTip. The 
reproducibility of the positioning is currently only visually controlled and so the xyz locations of 
the pre- and post-stimulation sampling areas are independent despite being apparently similar to 
the eye.  At the extremes, one of the two samplings would yield no detectable signal.  
A distinct question involves the nature of the released compounds.  To address this, 
identifications of released species can still be successfully made even without stimulation 
information. As previously mentioned , the quality of the spectral peaks provide an accurate mass 
that can be used to identify the species by comparison with identifications from MS/MS studies 
on tissue extracts of the same (or closely related) brain locations. Such previous studies were 
compiled; the sequences, monoisotopic neutral masses and source tissues were listed with all 
necessary species conversions made to the appropriate residues for Rattus norvegicus (Altelaar 
2009, Boonen 2007, Bora 2008, Caprioli 1997, Che 2006, Decaillot 2006, Dowell 2006, Lee 
2010, Parkin 2005, Zhang 2008). This list was referenced against consistently detected mass-to-
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charge ratios not seen in ZipTips controls. Listed in Table 3.5.1 are the peptides that appeared at 
least once in the SCN or SON that have been found in the aforementioned peptide list. Peptide 
identification validity is strong due to matches to the same tissue type as well as related peptides 
being observed together (e.g. multiple neurotensin fragments).  
 
3.4 FUTURE DIRECTIONS 
Future release experiments should first incorporate an improved ZipTip conditioning 
protocol to allow more peptides to bind and be retained during desalting. Some recent attempts 
have shown improved results and should be further tested. In general, the organic gradient (50% 
ACN for conditioning followed by 70% ACN for desalting) may need to be reversed to 
sufficiently release all possible polymer contaminants from the ZipTips before the sample is 
introduced. The most recent trials have used 100% ACN instead of 50% ACN used in the initial 
conditioning protocol. An ion-pairing agent like TFA may also be incorporated to further enhance 
binding of desired peptide species.  
A second improvement would be to provide a more localized stimulation to the region of 
interest in deter collection of the general mass release from the rest of the slice. This may be done 
by reduction of the slice size to eliminate tissue outside the region of interest. One possible study 
to supplement this effort would be to characterize the dynamics of the added stimulant in the 
brain slice chamber. This could be done by visualizing the diffusion of a colored stimulant 
replacement such as the addition of a dye (e.g. fast green). This way any contributing flow to the 
stimulant diffusion can be accounted for and controlled if needed. Lastly, the stimulations used 
here involved fairly universal and harsh stimulants such as KCl. Using electrical stimulation (such 
as via the retinohypothalamic tract) would eliminate issues with secretagogue application as this 
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would automatically involve stimulating the same neuronal structure. Thus, this likely will 
improve biological relevance and repeatability. 
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Table 3.1 Table of identifications of SCN and SON release in Rattus norvegicus mass-matched to 
fragmentation studies in the same model system (Bora 2008, Dowell 2006, Lee 2010, Millet 
2010). Other currently unidentified and commonly observed mass-to-charge ratios are also listed. 
Hi – hippocampus, Hy – hypothalamus, S - striatum.  
 
 
Peptide Name Theoretical 
m/z 
Observed 
m/z 
Mass Difference 
(ppm) 
Previous ID 
tissue 
  1295.68   
Cerebellin (57-71) 1495.78 1495.84 -35 SCN 
Neurotensin + Pyroglu (150-162) 1672.92 1672.91 4 SON, S, Hy 
  1776.78   
Neurotensin + Pyroglu (150-164) 1957.11 1957.06 26 SON 
  2029.01   
  2380.20   
Protachykinin-1 (72-95) 2580.33 2580.22 46 SCN 
Ac + Thymosin beta-10 (2-44) 4934.52 4934.98 -91 SON, Hi 
Ac + Thymosin beta-4 (2-44) 4961.48 4961.43 14 SON, Hi 
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CHAPTER 4 
 
MEASURING PEPTIDE RELEASE FROM IN VIVO 
MICRODIALYSIS OF THE RATTUS NORVEGICUS 
HIPPOCAMPUS 
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4.1 BACKGROUND 
Chemical signaling among neurons is the foundation for communication and transfer of 
information in the brain. It involves a diverse group of chemicals.  These include signaling 
peptides that contribute to various physiological processes and have multiple regulatory roles. 
Neuropeptides are neuron gene products that are packaged and released from large dense core 
vesicles into the extracellular space and are allowed to diffuse to their cellular targets (Strand 
1999, Gordon 2000, Bergquist 2009). Specifically, neuropeptides are a category of interest among 
intercellular, chemical-signaling molecules because of their involvement in such processes as 
behavior, learning, and memory (Strand 1999).  
One brain region intensively studied in neuroscience is the hippocampus, known for its 
roles in spatial memory and navigation (Burgess 2002). It is located in the medial temporal lobe 
and is shown in a coronal rat brain slice in Figure 4.5.1. Humans with damage or excision of the 
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hippocampal area exhibit deficits in declarative memory (Eichenbaum 2004). In rat hippocampal 
regions, there has been research on monitoring neurotransmitter levels (Zhang 2007), detecting 
specific peptides with labeled assays (Rocha 2003) and behavioral studies where single analytes 
are correlated to behavior that can be assessed with standard cognitive and behavioral 
performance tests (McNay 2006). It was in this particular study by our collaborator where it was 
shown that rats will have significant decreases in spontaneous alternation scores, a measure of 
working memory, in response to administration of systemic morphine. Since the hippocampus is 
known for memory roles, the results suggest that the morphine may be affecting response in that 
area and provide a good model for dynamic sampling of released peptides in response to a 
stimulus. 
To target stimulated peptide release, a comparison of peptide profiles between two or 
more conditional states can be made. This can be done by coupling an in vivo microdialysis 
method that will allow collection of release in response to stimuli as well as observation of 
behavior with a non-selective discovery method like mass spectrometry to finally be compared to 
prior sequencing information for identification.  
 
4.2 EXPERIMENTAL 
4.2.1 Animals. Male Sprague-Dawley rats (Harlan Laboratories, Madison, WI) were caged 
individually with food and water available ad libitum for at least one week before surgery. The 
rats were maintained on a 12 hr light-dark cycle with lights on at 0800.  Subjects were 3 months 
old and weighing between 315 and 350 g at the time of surgery. All procedures were approved by 
the University of Illinois at Urbana-Champaign Institutional Animal Care and Use Committee and 
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were in compliance with the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals. 
 
4.2.2 Surgery.  Subjects were anesthetized and bilaterally implanted with guide cannulae (CMA 
12, CMA/Microdialysis, Stockholm) by Ken Morris (Gold group) using sterile stereotaxic 
procedures. The guides were implanted into the left and right ventral hippocampus (5.8 mm back 
and 5.0 mm lateral from Bregma, 2.3 mm deep from dura).  Rats were allowed to recover from 
surgery for 1 week and then were handled daily for five consecutive days before the microdialysis 
procedure was conducted.  
 
4.2.3 Microdialysis Instrumentation. All microdialysis instrumentation and accessories are 
products of CMA/Microdialysis, Stockholm. A CMA/100 microinjection pump infuses artificial 
cerebral spinal fluid (aCSF all in mM: 128 NaCl; 3.0 KCl; 1.3 CaCl2; 1.0 MgCl2; 21.0 NaHCO3; 
1.3 NaH2PO4; 1.0 D-glucose, pH 7.4) from two 1 mL microsyringes (corresponding to left and 
right sides of the rat brain) to two lengths of fluorinated ethylene propylene tubing (ID 0.12 mm, 
volume 12 µL/m) connected by tubing adaptors at all junctions. A mounted swivel was connected 
to the microsyringes by 0.5 m of tubing on the inlets and 2.5 meters of tubing connected the 
swivel outlets. The longer lengths of tubing are held together with Parafilm M and threaded 
through a pair of suspended steel rings approximately 1 m over the rat (Figure 4.5.2). The ends 
are then connected to the inlets on the left and right microdialysis probes. On the outlets, a pair of 
0.5 m lengths of tubing were attached the perfusion output to a pair of Millipore 0.6 µL C18 
ZipTips.  
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4.2.4 Microdialysis Procedure. On the day of testing, rats had two CMA-12 20 kDa 
microdialysis probes briefly inserted and removed from their implanted guide cannulae and were 
allowed to rest for 1 hour.  After that time the rats were taken from their individual cages and 
placed in an opaque and open cylindrical holding chamber. The probes were reinserted and were 
perfused with aCSF at a rate of 2 µl/min. Perfusion continued for 1 hr 5 min before any samples 
were collected as shown in Figure 4.5.4. Samples were subsequently collected in 10 min intervals 
(20 µL perfusate) via solid phase extraction (SPE).   
 
4.2.5 Stimulation. Rats were subjected to up to two subsequent stimulus conditions per 
microdialysis experiment. The types were morphine injection and maze training.  
 
4.2.5.1 Morphine. The rat was removed from their cylindrical holding chamber and given a 
subcutaneous injection of morphine (5 mg/kg SC) or saline (0.9% NaCl) control into the dorsal 
surface of the animal. It was then replaced into their holding chamber where the subject was again 
free to move.  
 
4.2.5.2 Maze Training and Spontaneous Alternation Task. The training apparatus was an 
elevated plus-shaped maze with black Plexiglass floor and walls. The four identical maze arms 
were distinguished as A, B, C, and D corresponding to the cardinal directions S, E, N, and W 
respectively. Maze training was performed in a closed, lit room with directional cues on the walls. 
Maze training, if performed, would follow an injection by 30 min, (120.5 min after start of 
microdialysis). For each maze training trial, the rat was place into arm B facing the center of the 
maze. The subject was then free to move about the maze for 20 minutes (4 samples taken, 2 left-
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right sets). If the animal was stationary for 5 min in any one location, it was given a touch to the 
tail to restart movement. During the training time the animal’s order of arm visitation was 
recorded. A spontaneous alternation score was given based on a +1 point system for every 4 novel 
arms visited in any 5 consecutive visited arms.  
 
4.2.6 Solid Phase Extraction (SPE). The solid phase extraction was carried out by 0.6 µL C18 
ZipTips (Millipore Corporation, Billerica, MA). Two protocols concerning their preparation and 
use were employed between the early and later microdialysis experiments. Both protocols 
involved passing over the C18 material with a conditioning solution, washing solution, and an 
equilibration solution before exposure to sample. The ZipTips were attached by tubing adapters to 
the simultaneous left and right microdialysis outlets for ten minutes. After removal the ZipTips 
were either immediately washed and eluted onto a pre-spotted MALDI target or temporarily 
stored until the end of the experiment in 20 µL of wash solution in 0.5 mL microcentrifuge tubes. 
The early protocol consisted of the following solutions (volume of each step was 2 х 10 µL): 
conditioning sol. – 50/50 ACN/water, washing sol. – water, equilibration sol. – aCSF, and elution 
sol. 70/30 ACN/water. The later protocol consisted of the following solutions (again volume of 
each step was 2 х 10 µL): conditioning sol. –ACN, washing sol. – water + 0.1% TFA, 
equilibration sol. – aCSF, and elution sol. 70/30 ACN/water. Elution was carried out directly from 
the ZipTip on the analysis target through the use of a 100 µL Hamilton blunt syringe introducing 
the elution solvent from the inner side of the ZipTip. One ZipTip was eluted out as 5-6 0.2 µL 
spots and were allowed to air dry before analysis. Eluted samples were stored on the target in a 
case and storage bag at 4 °C before analysis.   
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4.2.7 Matrix Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry 
(MALDI-TOF MS). MALDI-TOF MS data was acquired on an Ultraflex II and Ultraflextreme 
TOF/TOF MS instruments (Bruker Daltonics, Bremen, Germany). Samples were eluted and 
spotted onto a Bruker/Eppendorf pre-spotted anchor chip target with alpha-cyan-4-
hydroxycinnamic acid (CHCA) matrix with along with pre-spotted calibrants on dedicated 
positions. Mass spectra were obtained in reflectron mode within 100 ppm mass accuracy. The 
mass-to-charge (m/z) range was initially 600-6000 with variable accumulations of shots (200-
1000). Later experiments were narrowed and standardized to aid in statistical analysis and 
scanned over the m/z range of 960-4000 and summed 1000 shots. Bruker FlexAnalysis software 
was used for spectra visualization and peak picking.  
 
4.2.8 Principal Component Analysis. Raw data files were uploaded in various folder structures 
to reflect the groups being compared with replicates kept in the same folders. Settings for spectra 
preparation included a resolution of 1000, baseline subtraction with Convex Hull algorithm, 
baseline flatness of 0.5, mass range of m/z 1000-4000 m/z, enabled Savitsky-Golay smoothing for 
5 cycles and a width of m/z 1.0, null spectra exclusion and support of spectra grouping. Peak 
calculation settings included peak picking on a total average spectrum with a signal-to-noise of 6 
and a 3% relative threshold base peak. Calculated peak statistics were used to determine 
significant peak differences between the groups.  
 
4.2.9 Tissue Extraction.  After decapitation both sides of the hippocampus were dissected out on 
ice within 7 min and were briefly rinsed with deionized water. 400-450 µL of preheated deionized 
water were added to the sample and continued to be heated for 10 min at 90°C, followed by 
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centrifugation at 14,000 × g for 10 min. The supernatant was saved and the tissue pellet was 
subjected to a second extraction stage. 400-450 µL of ice-cold acidified acetone (40:6:1, 
acetone/water/conc. HCl) was added to the sample before 1 min of sonication, 1 min of vortexing, 
and incubation on ice for 1 hr. The supernatant was saved again after another 1 min or vortexing 
and 20 min of centrifugation at 14,000 × g and 4 °C. A third extraction was performed on the 
tissue pellet with 400-450 µL of ice-cold 0.25% acetic acid and a 1 hr incubation on ice. The 
supernatant of this extraction was neutralized with 1 M NaOH and then dried to 25-35 µL with a 
SpeedVac to remove acetone. All three extracts were combined and filtered through a Microcon 
centrifugal filter (10 kDa MWCO). Lastly, the filtered extract was concentrated using a speed-
vac. 
 
4.2.10 Nano-Liquid Chromatography Fourier Transform Mass Spectrometry (LC-
FTMS/MS). This protocol is similar to that described in Lee 2010. The tissue extracts were 
analyzed using a 12 Tesla LTQ-FT Ultra (Thermo Fisher Scientific) online with a 1D NanoLC 
pump (Eksigent Technologies, Dublin, CA). The 25-35 µL samples were loaded with helium 
bomb pressure (500 psi) to a trap column (75 µm ID, ?OD) packed with 10 µm C18 solid phase 
particles (YMC Co, Ltd., Allentown, PA) and fritted with 5 mm of LiChrosorb (EM Separations, 
Gibbstown, NJ). The analytical column used was a ProteoPrep II medium (C18, 300 Å, 5 µm; 
New Objective, Woburn, MA). The flow rates was 300 nL/min with the following gradient: 0–10 
min, 0–10% B; 10–75 min, 10–30% B; 75–100 min, 30–45% B; 100–120 min, 45–60% B; 120–
125 min, 60–65% B; 125–126 min, 65–5% B; 126–132 min, 5–85% B; and 132-150 min, 85-5% 
B. Data acquisition consisted of a full scan event (m/z 290–2000; resolving power, m/∆m50% = 
90,000 in which ∆m50% is the mass spectral peak full width at half-maximum peak height) and 
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data-dependent CID MS/MS scans (40,000 resolving power) of the five most abundant peaks 
from the previous full scan. MS/MS settings included: isolation width, m/z 5; minimum signal 
threshold, 1000 counts; normalized collision energy, 35%; activation Q, 0.4; and activation time, 
50 ms. Dynamic exclusion was enabled with a repeat count of 4, an exclusion duration of 180 s, 
and a repeat duration of 30 s. 
 
4.2.11 Data Analysis and Database Searching. This process is also described in Lee 2010. Raw 
data files were analyzed using ProsightPC 2.0 (Thermo Fisher Scientific, Boyne 2009). Its 
component algorithm cRAWler 2.0 converted the raw data files (.raw) into ProSight upload files 
(.puf) composed of resolved isotopic distributions through the use of the Xtract algorithm. The 
.puf file from a single nano-LC-MS/MS run contained hundreds of MS1 and corresponding 
tandem MS (MS2) experiments and their resulting mass lists (within user-defined tolerances such 
as m/z range, retention time and signal-to-noise ratio), which could be searched against a 
sequence databases. A search tree was constructed where the first level searched the experiments 
for absolute masses (within ±10 ppm intact mass tolerance) against a database of predicted rat 
neuropeptides processed in silico through the NeuroPred algorithm (Southey 2006). The second 
level of the tree processed the experiments without identifications in the first mass search through 
the use of a “biomarker” mode search against an intact rat database compiled from UniProt 15.0 
and with parameter set to ±100 Da intact mass tolerance and ±10 ppm fragment mass tolerance. A 
Sequence Gazer tool was used for manually determining PTMs on the peptides. 
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4.3 RESULTS AND DISCUSSION 
The goal of this work was to measure the peptides released from the hippocampus during 
activity and morphine exposure. Unfortunately, the amount of peptide released was small so the 
first part was to create a database of hippocampus peptides.  This way released peptides could be 
matched to the list to provide identity information that can also hint at functional mechanisms.  
Peptide sequencing information can be compiled to provide a database of hippocampus 
peptides present in the tissue without connection to any stimulus. This involves discovering the 
peptide complement in a whole tissue extract through analysis with a high mass confidence 
method capable of analyzing a range of peptides at once. The specific instrument used on the 
tissue extracts was a 12 tesla Fourier transform ion cyclotron resonance mass spectrometer (FT-
ICR MS) with chemical separation by nano-liquid chromatography. The peptides detected in the 
hippocampi of two animals are listed in Table 4.1. This technique allowed for high mass accuracy 
of both intact and fragment mass-to-charge ratios necessary for confident identifications when 
searched against large proteomic databases as evidenced in the E-values also in Table 4.1 
(Boonen 2008, Mann 2008). Also, referencing previous studies with tandem mass spectrometry 
confirmed sequences in the same model system can contribute to the peptide lists as well (Altelaar 
2009, Boonen 2007, Bora 2008, Caprioli 1997, Che 2006, Decaillot 2006, Dowell 2006, Lee 
2010, Parkin 2005, Zhang 2008).  
The database is expected to hold the subset of interest, peptides that are released and seen 
in microdialysis, as well as protein fragments that may not be found in a release. To analyze the 
samples obtained through microdialysis, another instrument was used: matrix assisted laser 
desorption ionization time of flight mass spectrometry (MALDI-TOF MS). It is non-selective, 
robust, salt-tolerant and can detect trace levels of analyte in complex samples (Boonen 2008). It 
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has the advantage over FT MS instrumentation in terms of sensitivity, ability to analyze limited 
volume samples, and salt tolerance. The spectra from the experiment involving only acute 
morphine exposure and controls (n=8) were evaluated manually and through principal component 
analysis. The peak lists were searched against the created and compiled databases for mass-
matched identifications and putative matches were made but only two neuropeptide was seen in 
both the hippocampal extracts and the microdialysis samples: secretograinin-2 (571-573) and 
proenkephalin A (219-229).   
At this point, a list of masses had been compiled from each animal, as well as a partial but 
growing list of identified peptides from the same brain region. Next, would be to identify which 
peptides/peaks correspond to the observed behaviors. To further examine the spectra and perhaps 
point out mass-to-charge ratios to put more effort into identifying, the spectra of the treatment 
groups were compared. The side-by-side comparison (Figure 4.4) did appear to show some 
differences between the groups but the spectra were too complex to meaningfully analyze 
manually. 
Since the spectra are complex, a statistical approach was used to help simplify the data to 
the main differences between the groups. The tool to be used was principal component analysis 
software specific to MALDI MS data to enhance the eye in looking for differences between the 
treatment groups. Bruker ClinProTools software was used to reduce data complexity and 
distinguish major differences between conditional groups. Two comparisons were made to try to 
show the major contributions to variation in the data set. First, the data were organized by 
treatment group, which showed little clustering as seen in Figure 4.5. The second organization 
was by animal and this seemed to better define the variation and show that two sets of mass-to-
charge ratios were responsible for most of the variation. Major contributors to PC1 included m/z 
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1121.5 and 1249.6, while 1209.5 and 1337.6 contributed mostly to PC2 (Table 4.2.). If presence 
of these m/z values was correlated to rats, there was a seemingly random separation among the 
rats. Four rats (2 morphine and 2 saline treated) display variable integration areas of PC1 
components and constant areas of PC2 with the opposite true for the other four rats (again 2 
morphine and 2 saline treated). A possible biological explanation for the separation shown by the 
first two principle components is the occurrence of a coding region single nucleotide 
polymorphism (SNP) resulting in a peptide that exists in two forms (Tost 2002). The other 
support for the peptides being related is that both pairs share the same difference of 128.1 Da, 
which may be the loss of an amino acid residue of lysine or glutamine. 
 
4.4 FUTURE DIRECTIONS 
 The results show some variation in the data set but unfortunately it does not relate to the 
goal of finding differences due to stimulant conditions. As it is not described here, further analysis 
of the other treatment experiments (including the maze training) may reveal treatment specific 
changes that can be correlated to performance and essentially working memory. However, due to 
an instrument setting (cubic enhanced calibration vs. quadratic calibration), a recalibration will be 
required before being able to analyze this data through the same PCA software.  
 A new set of experiments under controlled conditions optimal for PCA analysis is also 
underway. The microdialysis samples are being acquired under automatic acquisition optimized 
to eliminate human bias towards saving spectra and to collect consistent shot counts from sample 
to sample. At the same time these same animals are being dissected immediately following their 
microdialysis testing to further correlate and identify peptides seen in microdialysis through tissue 
extraction and subsequent nano-LC FTMS analysis. Preliminary comparisons to the previous 
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acute morphine exposure experiments confirm the presence of the same mass-to-charge values as 
well as enhancing others that were more rarely seen under the previous acquisition conditions. 
PCA of these animals may give more pronounced differences especially using a so-called 
‘biomarker’ training set option that will evaluate small differences between the treatment groups.  
 The consistent release and detection of protein fragments is interesting. Could they be an 
example of a non-classical type of neuropeptide or are they a blood contaminant from disturbing 
the tissue during probe insertion (Gomes 2010, Gelman 2010)? More work would be needed to 
confirm this. Infusion of the fibrinogen fragments by microdialysis or use as a tissue slice 
stimulant may give a response that can give clues to its function in the brain. If the addition of the 
protein fragments themselves caused a detectable change or release, their presence in the 
hippocampus may be the result of more than just the degradation of blood. A control for this 
could be performed by implanting probes in a different brain region to see if their presence is not 
ubiquitous.  
 In reference to using stimulants and better assessing their responses, it would be helpful to 
improve temporal resolution to the current microdialysis set-up. A future direction for the work is 
to integrate an oil plug system similar to that described in Wang 2008 to package peptide 
response that could be much easier correlated with the chemical or training stimulation.  
Future experiments may also incorporate an evaluation of the microdialysis output not 
retained on the ZipTip. This can be analyzed via CE-MS for separation and detection of the 
smaller and important mass range that includes small molecule neurotransmitters known to play a 
role in memory.   
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Table 4.1 Table of prohormone processed peptides identified from hippocampal tissue extracts 
from two rat subjects. Starred peptides were seen in both the microdialysis and hippocampus 
extract. E-value is a measure of confidence = P-score х database size with confident identification 
confirmed at E-value of 1E-4 or less.  
 
 
  Prohormone 
Description 
Peptide 
Name 
Fragment Sequence Theoretical 
Mass 
Mass 
Diff 
(ppm) 
Mass 
Diff 
(Da) 
E Value
1  Cerebellin‐1  Cerebellin  57‐72  SGSAKVAFSAIRSTNH 1631.84 0.88  0  1.29E‐34
2  Cholecystokinin    36‐44  AEEAPRRQL 1068.57 0.88  0  3.27E‐08
3  Cholecystokinin    46‐57  AVLRPDSEPRAR 1365.75 0.68  0  3.00E‐09
4  Cholecystokinin    46‐60  AVLRPDSEPRARLGA 1606.89 ‐0.1  0  4.42E‐09
5  Cholecystokinin    72‐94  APSGRMSVLKNLQGLDPSHRISD 2477.28 1.14  0  1.69E‐36
6  Cholecystokinin    71‐94  KAPSGRMSVLKNLQGLDPSHRISD 2605.38 1.82  0  1.87E‐06
7  Neurogranin    59‐75  GGPGGAGGARGGAGGGP 1208.57 0.19  0  1.05E‐25
8  ProSAAS  Little SAAS  42‐59  SLSAASAPLAETSTPLRL 1783.97 0.86  0  2.15E‐34
9  Proenkephalin A    198‐209  SPQLEDEAKELQ 1385.67 0.6  0  4.91E‐33
10  Proenkephalin A*    219‐229  VGRPEWWMDYQ 1465.64 1.18  0  1.53E‐16
11  Proenkephalin A    239‐260  FAESLPSDEEGESYSKEVPEME 2488.05 1.3  0  1.16E‐35
12  Proenkephalin A    143‐185  DADEGDTLANSSDLLKELLGTGDNRAKDS‐
HQQESTNNDEDSTS 
4592.01 1.01  0  1.94E‐20
13  Secretogranin‐1    435‐451  LLDEGHDPVHESPVDTA 1829.84 1.06  0  1.87E‐34
14  Secretogranin‐1    416‐432  GRGREPGAYPALDSRQE 1857.91 0.5  0  5.34E‐15
15  Secretogranin‐1    513‐532  LGALFNPYFDPLQWKNSDFE 2400.14 0.6  0  6.76E‐40
16  Secretogranin‐2*    571‐583  IPAGSLKNEDTPN 1354.67 0.91  0  8.10E‐28
17  Somatostatin    89‐100  SANSNPAMAPRE 1243.56 0.75  0  1.01E‐27
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